Tonix Pharmaceuticals (TNXP) - 2024 Q1 - Quarterly Results

Tonix Pharmaceuticals Holding Corp. - 8-K Exhibit 99.01 Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second quarter 2024 TNX-102 SL for the treatment of acute stress reaction (ASR) and acute stress disorder (ASD), and prophylaxis against development of posttraumatic stress disorder (PTSD) Commercial planning continues for U.S. launch of Tonmy ...